Fourth Humira biosimilar set for EU approval
Deal with Amgen signals exclusivity until 2023 for mega-blockbuster
Sales of Humira could peak above $18 billion – CEO
Amgen’s biosimilar is ready to go, but AbbVie believes it can delay until 2022
Ablynx’s vobarilizumab seen as key should Humira sales fall.
ABP 501 gets backing from FDA panel.
Gamble on opicinumab looks unlikely to pay off.
Abbott’s blockbuster rheumatoid arthritis drug, Humira, has been approved by the US FDA for a new use – to treat patients with moderate to severe ulcerative colitis. Abbott Laboratories Inc.’s drug, Humira, has been approved for the treatment of moderate to…